Skip to main content
. Author manuscript; available in PMC: 2009 Oct 28.
Published in final edited form as: Clin Pharmacol Ther. 2007 Oct 31;82(6):700–710. doi: 10.1038/sj.clpt.6100409

Figure 3.

Figure 3

Schema for phase I clinical trial to assess the safety, maximum tolerated dose, and preliminary efficacy of MV-NIS administered intravenously with and without cyclophosphamide in patients with relapsed or refractory multiple myeloma. Correlative studies performed are summarized in the table of this figure.